AAAAAA
Results: 1-25/46
Authors:
Ponten, F
Lindman, H
Bostrom, A
Berne, B
Bergh, J
Citation: F. Ponten et al., Induction of p53 expression in skin by radiotherapy and UV radiation: A randomized study, J NAT CANC, 93(2), 2001, pp. 128-133
Authors:
Symniotis, E
Johansson, B
Bergh, J
Lehtinen, B
Sundel, PE
Reutersvard, P
Citation: E. Symniotis et al., Investigation of the corrosion properties of electrically-conductive surface coatings, SURF COAT I, 84(4), 2001, pp. 285-291
Authors:
Warnberg, F
Bergh, J
Zack, M
Holmberg, L
Citation: F. Warnberg et al., Risk factors for subsequent invasive breast cancer and breast cancer deathafter ductal carcinoma in situ: A population-based case-control study in Sweden, CANC EPID B, 10(5), 2001, pp. 495-499
Authors:
Lampic, C
Thurfjell, E
Bergh, J
Sjoden, PO
Citation: C. Lampic et al., Short- and long-term anxiety and depression in women recalled after breastcancer screening, EUR J CANC, 37(4), 2001, pp. 463-469
Authors:
Sjostrom, J
Bergh, J
Citation: J. Sjostrom et J. Bergh, How apoptosis is regulated, and what goes wrong in cancer, BR MED J, 322(7301), 2001, pp. 1538-1539
Authors:
Phillips, N
Bergh, J
Oren, R
Linder, S
Citation: N. Phillips et al., Effects of nutrition and soil water availability on water use in a Norway spruce stand, TREE PHYSL, 21(12-13), 2001, pp. 851-860
Authors:
Hakamies-Blomqvist, L
Luoma, ML
Sjostrom, J
Pluzanska, A
Sjodin, M
Mouridsen, H
Ostenstad, B
Mjaaland, I
Ottosson, S
Bergh, J
Malmstrom, PO
Blomqvist, C
Citation: L. Hakamies-blomqvist et al., Timing of quality of life (QoL) assessments as a source of error in oncological trials, J ADV NURS, 35(5), 2001, pp. 709-716
Authors:
Glimelius, B
Bergh, J
Brandt, L
Brorsson, B
Gunnars, B
Hafstrom, L
Haglund, U
Hogberg, T
Janunger, KG
Jonsson, PE
Karlsson, G
Kimby, E
Lamnevik, G
Nilsson, S
Permert, J
Ragnhammar, P
Sorenson, S
Nygren, P
Citation: B. Glimelius et al., The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of chemotherapy effects in some major tumour types - Summary and conclusions, ACTA ONCOL, 40(2-3), 2001, pp. 135-154
Authors:
Bergh, J
Jonsson, PE
Glimelius, B
Nygren, P
Citation: J. Bergh et al., A systematic overview of chemotherapy effects in breast cancer, ACTA ONCOL, 40(2-3), 2001, pp. 253-281
Authors:
Ciray, I
Lindman, H
Astrom, KGO
Bergh, J
Ahlstrom, KH
Citation: I. Ciray et al., Early response of breast cancer bone metastases to chemotherapy evaluated with MR imaging, ACT RADIOL, 42(2), 2001, pp. 198-206
Authors:
Bostrom, A
Lindman, H
Swartling, C
Berne, B
Bergh, J
Citation: A. Bostrom et al., Potent corticosteroid cream (mometasone furoate) significantly reduces acute radiation dermatitis: results from a double-blind, randomized study, RADIOTH ONC, 59(3), 2001, pp. 257-265
Authors:
Hall, KS
Wiklund, T
Erikstein, B
Holte, H
Kvalheim, G
Sommer, HH
Andersen, A
Skovlund, E
Bergh, J
Hall, C
Citation: Ks. Hall et al., Effects of dose-intensive chemotherapy and radiotherapy on serum n-terminal proatrial natriuretic peptide in high-risk breast cancer patients, BREAST CANC, 67(3), 2001, pp. 235-244
Authors:
Norberg, T
Klaar, S
Lindqvist, L
Lindahl, T
Ahlgren, J
Bergh, J
Citation: T. Norberg et al., Enzymatic mutation detection method evaluated for detection of p53 mutations in cDNA from breast cancers, CLIN CHEM, 47(5), 2001, pp. 821-828
Authors:
Linderholm, BK
Lindahl, T
Holmberg, L
Klaar, S
Lennerstrand, J
Henriksson, R
Bergh, J
Citation: Bk. Linderholm et al., The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer, CANCER RES, 61(5), 2001, pp. 2256-2260
Authors:
Norberg, T
Klaar, S
Karf, G
Nordgren, H
Holmberg, L
Bergh, J
Citation: T. Norberg et al., Increased p53 mutation frequency during tumor progression - Results from abreast cancer cohort, CANCER RES, 61(22), 2001, pp. 8317-8321
Authors:
Sjostrom, J
Blomqvist, C
Heikkila, P
von Boguslawski, K
Raisanen-Sokolowski, A
Bengtsson, NO
Mjaaland, I
Malmstrom, P
Ostenstadt, B
Bergh, J
Wist, E
Valvere, V
Saksela, E
Citation: J. Sjostrom et al., Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer, CLIN CANC R, 6(8), 2000, pp. 3103-3110
Authors:
Hakamies-Blomqvist, L
Luoma, ML
Sjostrom, J
Pluzanska, A
Sjodin, M
Mouridsen, H
Ostenstad, B
Mjaaland, I
Ottosson-Lonn, S
Bergh, J
Malmstrom, PO
Blomqvist, C
Citation: L. Hakamies-blomqvist et al., Quality of life in patients with metastatic breast cancer receiving eitherdocetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian Breast Group, EUR J CANC, 36(11), 2000, pp. 1411-1417
Authors:
Dummer, R
Bergh, J
Karlsson, Y
Horovitz, JA
Mulder, NH
Huinin, DT
Burg, G
Hofbauer, G
Osanto, S
Citation: R. Dummer et al., Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors, CANC GENE T, 7(7), 2000, pp. 1069-1076
Authors:
von Heideman, A
Sandstrom, M
Csoka, K
Tholander, B
Larsson, R
Bergh, J
Nygren, P
Citation: A. Von Heideman et al., Evaluation of drug interactions in the established FEC regimen in primary cultures of tumour cells from patients, ANN ONCOL, 11(10), 2000, pp. 1301-1307
Authors:
Lindman, H
Jansson, T
Arnberg, H
Bergh, J
Einarsson, R
Citation: H. Lindman et al., Serum markers TPS, TPA and CA 15-3 as monitors of chemotherapy in patientswith metastatic breast cancer, J TUMOR M, 15(3), 2000, pp. 177-186
Authors:
Lindahl, T
Engel, G
Ahlgren, J
Klaar, S
Bjohle, J
Lindman, H
Andersson, J
von Schoultz, E
Bergh, J
Citation: T. Lindahl et al., Can axillary dissection be avoided by improved molecular biological diagnosis?, ACTA ONCOL, 39(3), 2000, pp. 319-326
Authors:
Thurfjell, MG
Jansson, T
Nordgren, H
Bergh, J
Lindgren, A
Thurfjell, E
Citation: Mg. Thurfjell et al., Local breast cancer recurrence caused by mammographically guided punctures, ACT RADIOL, 41(5), 2000, pp. 435-440
Authors:
Ciray, I
Astrom, G
Andreasson, I
Edekling, T
Hansen, J
Bergh, J
Ahlstrom, H
Citation: I. Ciray et al., Evaluation of new sclerotic bone metastases in breast cancer patients during treatment, ACT RADIOL, 41(2), 2000, pp. 178-182
Authors:
Einarsson, R
Lindman, H
Bergh, J
Citation: R. Einarsson et al., Use of TPS and CA 15-3 assays for monitoring chemotherapy in metastatic breast cancer patients, ANTICANC R, 20(6D), 2000, pp. 5089-5093
Authors:
Bergh, J
Citation: J. Bergh, Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial (vol 356, pg 1384, 2000), LANCET, 356(9248), 2000, pp. 2196-2196